OncoTribune Contents

OncoTribune コンテンツ紹介

学会速報レポート

Congress Report

海外学会などで発表されたホットでタイムリーな演題を専門医が厳選。レポートとコメントを掲載します。

臨床試験サマリ

Executive Summary of Cancer Clinical Trials

各領域で発表されている臨床試験を分かりやすくサマライズして掲載します。

座談会

Round Table Discussion

各領域のエキスパートによるディスカッションした内容を掲載します

Latest Updates

新着コンテンツ

ESMO Congress 2019 FLASH REPORT - 526PD -

TRIUMPH: Primary efficacy of a phase II trial of trastuzumab (T) and pertuzumab (P) in patients (pts) with metastatic colorectal cancer (mCRC) with HER2 (ERBB2) amplification (amp) in tumour tissue or circulating tumour DNA (ctDNA): A GOZILA sub-study

ESMO Congress 2019 FLASH REPORT - 525O -

ACHIEVE-2 trial: a randomized phase III trial investigating duration of adjuvant (adj) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with high-risk stage II colon cancer (CC)

ESMO Congress 2019 FLASH REPORT - 11740 -

Pembrolizumab in microsatellite instability high cancer: Updated analysis of the phase II KEYNOTE-164 and KEYNOTE-158 studies
L.A. Diaz, D. Le, M. Maio, et al.

ESMO Congress 2019 FLASH REPORT - Abstract LBA11 -

Nivolumab Versus Chemotherapy in Advanced Esophageal Squamous Cell Carcinoma : The ATTRACTION-3 study / Cho BC, et al

ESMO Congress 2019 FLASH REPORT - Abstract LBA33 -

Lefitolimod vs standard of care (SOC) for patients with metastatic colorectal cancer (mCRC) responding to first-line standard treatment: Results from the randomized phase III IMPALA trial. / Salazar R, et al.

ESMO Congress 2019 FLASH REPORT - LBA30_PR -

Analysis of circulating tumour DNA (ctDNA) from patients enrolled in the IDEA-FRANCE phase III trial: Prognostic and predictive value for adjuvant treatment duration (ID 5478)

ESMO Congress 2019 FLASH REPORT - 4511 -

POLO: Health-related quality of life (HRQoL) of olaparib maintenance treatment versus placebo in patients with a germline BRCA mutation and metastatic pancreatic cancer

ESMO Congress 2019 FLASH REPORT - Abstract 2449 -

Conversion rate in locally advanced pancreatic cancer (LAPC) after nab-Paclitaxel/Gemcitabine-vs。FOLFIRINOX-based induction chemotherapy (NEOLAP_AIO-PAK-013 Trial). / V. Kunzmann, et al.

ESMO Congress 2019 FLASH REPORT - Abstract LBA90 -

Abstract LBA90
Primary analysis results of randomized controlled trial evaluating reactive topical corticosteroid strategies for the facial acneiform rash by EGFR inhibitors(EGFRIs) in patient(pts) with RAS wildtype(wt) metastatic colorectal cancer(mCRC) -FAEISS study-. / Yamazaki N, et al.

ESMO Congress 2019 FLASH REPORT - Abstract LBA43 -

Randomized phase 3 ANGEL study of rivoceranib (apatinib) + best supportive care (BSC) vs placebo + BSC in patients with advanced/metastatic gastric cancer who failed ≥2 prior chemotherapy regimens / Kang Y-K, et al.